CAJ | 학술논문

目的：探讨吉西他滨对胰腺癌外周血调节性T细胞的影响，为进一步提高过继免疫治疗的疗效提供依据和参考。方法本研究入选2012年1月至2014年10月收治的32例胰腺癌患者，分为吉西他滨组（吉西他滨＋过继免疫治疗）和对照组（单纯过继免疫治疗），观察两组患者治疗前后外周血调节性 T细胞水平、化疗不良反应，并对两组患者的生存时间进行分析比较。结果吉西他滨组患者治疗后外周血调节性T细胞水平较治疗前显著降低，与对照组相比亦显著降低，两组比较有统计学差异（P＜0．05），吉西他滨组中位生存时间较对照组延长1．3个月（10．0个月与8．7个月比较）。结论吉西他滨化疗可以显著降低胰腺癌患者外周血调节性T细胞水平，有效调节患者的肿瘤免疫耐受，提高过继免疫治疗的疗效。
목적：탐토길서타빈대이선암외주혈조절성T세포적영향，위진일보제고과계면역치료적료효제공의거화삼고。방법본연구입선2012년1월지2014년10월수치적32례이선암환자，분위길서타빈조（길서타빈＋과계면역치료）화대조조（단순과계면역치료），관찰량조환자치료전후외주혈조절성 T세포수평、화료불량반응，병대량조환자적생존시간진행분석비교。결과길서타빈조환자치료후외주혈조절성T세포수평교치료전현저강저，여대조조상비역현저강저，량조비교유통계학차이（P＜0．05），길서타빈조중위생존시간교대조조연장1．3개월（10．0개월여8．7개월비교）。결론길서타빈화료가이현저강저이선암환자외주혈조절성T세포수평，유효조절환자적종류면역내수，제고과계면역치료적료효。
Objective To investigate the influence of gemcitabine chemotherapy on levels of regulatory Tcells (Tregs) in peripheral blood for patients with pancreatic cancer and provide evidence and reference for improving the efficacy of adoptive im-munotherapy .Methods 32 patients were enrolled in this study from January 2012 to October 2014 ,among whom 16 received gemcitabine chemotherapy combined with adoptive immunotherapy (gemcitabine group) ,the other 16 patients received adoptive immunotherapy only(control group) .The level of Tregs in peripheral blood ,side effect and overall survival were observed be-fore and after the therapy .Results The number of Tregs in peripheral blood was significantly decreased after gemcitabine chemotherapy ,and it was also lower than that of the control group .The overall survival time of the gemcitabine group was 1.3 mo longer than the control group(10 .0 mo vs 8 .7 mo) .Conclusion Therapeutic regimen of gemcitabine can remarkly de-plete Tregs in peripheral blood of patients with pancreatic cancer ,effectively regulate tumor immune tolerance ,and improve the efficacy of adoptive immunotherapy .